Onyx Drug Fails Late Stage Trial

Late stage clinical trials of Onyx Pharmaceuticals Inc. (ONXX) and Bayer AG's (BAY) kidney cancer treatment Nexavar failed to increase survival rates in patients. Shares of Onyx plunged $3.00 to close at $16.82 while Bayer stock eased 91 cents to close at $43.89.